Pharma Fridays – Sept. 27, 2024

September 27, 2024

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * TEPEZZA Receives Approval in Japan to Treat TED On Sept. 24, Amgen announced that TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) thyroid eye disease (TED) by Japan’s Ministry of Health, Labour and Welfare (MHLW). […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Pharma Fridays

←Pregnant Women With SSD May Have Children with Developmental Delays

Oral Arguments: Getting the Word Out About Oral TRT→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today